Five-Year Retrospective Study Shows Topline Results for Patients Treated with Sensus Healthcare’s Superficial Radiation Therapy
Sensus Healthcare, Inc. announces topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients.
Read the full press release here.
Sensus Healthcare Mentioned in SFBJ’s Business of Medicine: ‘It’s an exciting time for the life sciences in Florida’
Sensus Healthcare Signs R&D Agreement to Collaborate with Perelman School of Medicine at the University of Pennsylvania on World’s First Sculptura™ Intraoperative Radiation Therapy System
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries